|

Remotely-supervised Neuromodulation in PPA

RECRUITINGN/ASponsored by University of Texas at Austin
Actively Recruiting
PhaseN/A
SponsorUniversity of Texas at Austin
Started2026-01
Est. completion2029-05
Eligibility
Age40 Years+
Healthy vol.Accepted
Locations2 sites

Summary

The goal of this clinical trial is to learn whether remotely-supervised transcranial direct-current stimulation (RS-tDCS) can improve speech and language treatments for individuals with logopenic variant primary progressive aphasia (lvPPA). tDCS is a form of brain stimulation where a low-level electrical current is delivered to the brain through electrodes placed on the head. The main questions the trial aims to answer are: * Is it feasible to do RS-tDCS with virtual speech therapy? * How can brain magnetic resonance imaging scans (MRIs) predict how well someone will benefit from RS-tDCS with virtual speech therapy? Researchers will compare active RS-tDCS stimulation to sham stimulation (where there is no active stimulation, but participants feel stimulation effects at the beginning and end of the session). Participants will: * Travel to either the University of California, San Francisco (UCSF) or the University of Texas at Austin (UT Austin) one time for in-person testing, an MRI scan, and training on how to use the RS-tDCS equipment * Meet with a speech-language pathologist for pre-treatment testing on Zoom for 2 weeks * Participate in speech-language therapy and independent practice on Zoom 5 days a week for 4 weeks, using either active tDCS stimulation or sham * Complete post-treatment testing on Zoom for 1-2 weeks * Complete follow-up testing 2 months after completion of treatment

Eligibility

Age: 40 Years+Healthy volunteers accepted
Inclusion Criteria:

* Meets diagnostic criteria for primary progressive aphasia (PPA)
* Meets diagnostic criteria for logopenic variant PPA
* Score of 20 or higher on the Mini-Mental State Examination
* Adequate hearing and vision (with hearing or vision aids, if needed)
* Has a study partner that can co-enroll in the study and attend pre-treatment training as well as continue to be present for teleconference meetings, as needed
* Able and willing to undergo MRI brain scan
* Access to high speed internet and basic experience using a computer and the internet
* Individuals should be fluent speakers of English

Exclusion Criteria:

* Speech and language deficits better accounted for by another neurological disorder
* Does not meet diagnostic criteria for logopenic variant PPA
* Score of less than 20 on the Mini-Mental State Examination
* Does not have a study partner who can co-enroll in the study
* Contraindications for tDCS or MRI scan (History of seizures, head injury, craniotomy, skull surgery or fracture; History of severe or frequent migraines; Metallic implant in head or any metal in head; Pacemaker or cardioverter-defibrillator or any other stimulator; Chronic skin problems; Pregnancy)
* History of stroke, epilepsy, or significant brain injury

Conditions7

Alzheimer's DiseaseLogopenic Progressive Aphasia (LPA)Logopenic Variant Primary Progressive AphasiaLogopenic Variant of Primary Progressive Aphasia (LPA)Primary Progressive Aphasia(PPA)Progressive AphasiaProgressive Aphasia in Alzheimer's Disease

Locations2 sites

California

1 site
UCSF Memory and Aging Cener
San Francisco, California, 94158
Willa Keegan-Rodewald, M.A.willa.keeganrodewald@ucsf.edu

Texas

1 site
University of Texas
Austin, Texas, 78712
Aphasia Lab Research Coordinator, MS512-471-3420aphasialab@austin.utexas.edu

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.